Patents by Inventor Dan Peer

Dan Peer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20130129752
    Abstract: Disclosed herein are is a leukocyte-selective delivery agent comprising, a targeting moiety that selectively binds LFA-I, a protein carrier moiety covalently linked to the targeting moiety, and a therapeutic agent associated with the carrier moiety. The delivery agent may be further selective for activated leukocytes, wherein the targeting moiety selectively binds LFA-I in its activated conformation. The targeting moiety comprises an antibody or functional fragment thereof, such as an scFV. Examples of antibodies or fragments thereof which selectively bind LFA-I activated conformation bind to the locked open I domain of LFA-I, or binds to the leg domain of the ?2 subunit of LFA-I ((ILP2)—The antibody or functional fragment thereof may alternatively bind non-selectively to both low affinity and high affinity LFA-I. Examples of a non-protein carrier are a basic polypeptide such as protamine or a functional fragment thereof. One such fragment is RSQSRSRYYRQRQRSRRRRRRS.
    Type: Application
    Filed: April 25, 2007
    Publication date: May 23, 2013
    Applicant: IMMUNE DISEASE INSTITUTE, INC.
    Inventors: Dan Peer, Motomu Shimaoka, Judy Lieberman
  • Patent number: 8277847
    Abstract: Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal.
    Type: Grant
    Filed: February 13, 2009
    Date of Patent: October 2, 2012
    Assignee: Tel Aviv University Future Technology Development L.P.
    Inventors: Rimona Margalit, Dan Peer
  • Publication number: 20120171261
    Abstract: The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery.
    Type: Application
    Filed: March 14, 2012
    Publication date: July 5, 2012
    Applicant: Tel-Aviv University Future Technology Development L.P.
    Inventors: Rimona MARGALIT, Noga Yerushalmi, Dan Peer, Ilia Rivkin
  • Publication number: 20120129916
    Abstract: A method of generating a particle is disclosed, the particle being for delivery of a polynucleotide to a target cell. The method comprises (a) contacting the polynucleotide with a composition comprising cationic molecules, wherein the cationic molecules condense the polynucleotide by electrostatic interactions to generate a complex, wherein the cationic molecules are not comprised in a liposome; and (b) covalently binding the complex to a targeting moiety at a pH equal to or below about 4.5, thereby generating the particle for delivery of the polynucleotide agent to the target cell. Use of the particles and compositions comprising same are also disclosed.
    Type: Application
    Filed: July 29, 2010
    Publication date: May 24, 2012
    Applicant: RAMOT AT TEL-AVIV UNIVERSITY LTD.
    Inventor: Dan Peer
  • Patent number: 8178129
    Abstract: The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery.
    Type: Grant
    Filed: November 2, 2005
    Date of Patent: May 15, 2012
    Assignee: Tel-Aviv University Future Technology Development L.P.
    Inventors: Rimona Margalit, Noga Yerushalmi, Dan Peer, Ilia Rivkin
  • Publication number: 20110177155
    Abstract: The present invention generally relates to methods and compositions for the simultaneous delivery of at least one insoluble agent and at least one soluble agent to a cell. In particular the present invention relates to methods and compositions for the dual delivery of an insoluble agent and a soluble agent to a particular target cell, for example, a leukocyte or endothelial cell. In particular, methods and compositions for simultaneous delivery of a hydrophilic (i.e. soluble) agent and/or a hydrophobic (i.e. insoluble) agent to a leukocyte cell or endothelia cell are disclosed.
    Type: Application
    Filed: August 20, 2008
    Publication date: July 21, 2011
    Applicant: IMMUNE DISEASE INSTITUTE, INC.
    Inventors: Dan Peer, Motomu Shimaoka
  • Publication number: 20100285002
    Abstract: In one aspect, the invention relates to the treatment and/or prevention of inflammation by inhibition of cyclin D1. In one embodiment, Th1-mediated inflammation is selectively inhibited or reduced by a method comprising administering an agent that inhibits cyclin D1. In another embodiment, an autoimmune disease or a disorder characterized by or involving a Th1 inflammatory response is treated or prevented in a subject by a method comprising administering to the subject an agent that inhibits cyclin D1.
    Type: Application
    Filed: December 30, 2008
    Publication date: November 11, 2010
    Applicant: IMMUNE DISEASE INSTITUTE, INC.
    Inventors: Dan Peer, Motomu Shimaoka
  • Publication number: 20100008937
    Abstract: Disclosed are delivery agents for selective delivery to leukocytes. The leukocyte-selective delivery agents comprise a targeting moiety that selectively binds LFA-I, a non-protein carrier moiety covalently linked to the targeting moiety and a therapeutic agent associated with the carrier moiety. The non-protein carrier moiety comprises a liposome, a micelle, or a polymeric nanoparticle comprised of PLA or PLGA. The delivery agent may be further selective for activated leukocytes by using a targeting moiety that selectively binds LFA-I in its activated conformation. The targeting moiety may comprise an antibody or functional fragment thereof such as an scFV. Appropriate therapeutic agents include a nucleic acid, a small molecule, a polypeptide, and an antibody or functional fragment thereof. Additional examples of therapeutic agents are a small RNA, an antagomir, an LNA, or an antisense oligonucleotide. One such therapeutic agent is an RNA interference molecule such as siRNA, dsRNA, stRNA, shRNA, miRNA.
    Type: Application
    Filed: April 25, 2007
    Publication date: January 14, 2010
    Applicant: IMMUNE DISEASE INSTITUTE, INC.
    Inventors: Dan Peer, Motomu Shimaoka
  • Publication number: 20090232730
    Abstract: The invention provides a method for a multi-layered lipid particles in the form of liposomes that are coated first with a cryoprotectant followed by a targeting moiety over the coat of cryoprotectant, and a method for encapsulating drugs and agents in the multi-layered coated liposomes. In addition, ready-to-use liposome kits for coating with targeting agent of choice and for drug and/or agent encapsulation.
    Type: Application
    Filed: April 24, 2007
    Publication date: September 17, 2009
    Applicant: IMMUNE DISEASE INSTITUTE, INC.
    Inventors: Dan Peer, Motomu Shimaoka
  • Publication number: 20090155178
    Abstract: Lipidated glycosaminoglycan particles, prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaminoglycan with a primary amine in the lipid, are used to encapsulate drugs for use in the treatment of pathological conditions in an animal.
    Type: Application
    Filed: February 13, 2009
    Publication date: June 18, 2009
    Applicant: RAMOT AT TEL AVIV UNIVERSITY LTD.
    Inventors: Rimona MARGALIT, Dan Peer
  • Patent number: 7544374
    Abstract: Lipidated glycosaminoglycan particles are prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaiminoglycan with a primary amine in the lipid. These particles can be used to encapsulate active ingredients, such as drugs for use in the treatment of pathological conditions in an animal.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: June 9, 2009
    Assignee: Tel Aviv University Future Technology Development L.P.
    Inventors: Rimona Margalit, Dan Peer
  • Publication number: 20090022656
    Abstract: Lipidated micro- or macroparticles are prepared by covalently linking a glycoprotein, typically collagen, with at least one lipid. An amino group in the glycoprotein is joined with a primary amine in the lipid. These particles can be used to encapsulate active ingredients, such as drugs.
    Type: Application
    Filed: July 8, 2005
    Publication date: January 22, 2009
    Inventors: Rimona Margalit, Dan Peer
  • Publication number: 20080248092
    Abstract: The invention provides a formulation of water insoluble or poorly water soluble drugs encapsulated in lipidated glycosaminoglycan particles for targeted drug delivery.
    Type: Application
    Filed: November 2, 2005
    Publication date: October 9, 2008
    Inventors: Rimona Margalit, Noga Yerushalmi, Dan Peer, Ilia Rivkin
  • Publication number: 20040266882
    Abstract: A method of treating a subject having cancer, particularly a multidrug resistance cancer, which comprises administering to the subject at least one chemotherapeutic agent and at least one 3-aryloxy-3-phenylpropylamine and pharmaceutical compositions and kits for implementing the method.
    Type: Application
    Filed: March 8, 2004
    Publication date: December 30, 2004
    Inventors: Rimona Margalit, Dan Peer
  • Publication number: 20040241248
    Abstract: Lipidated glycosaminoglycan particles are prepared by reacting a glycosaminoglycan with at least one lipid to cross-link the carboxylic acid groups in the glycosaiminoglycan with a primary amine in the lipid. These particles can be used to encapsulate active ingredients, such as drugs for use in the treatment of pathological conditions in an animal.
    Type: Application
    Filed: July 19, 2004
    Publication date: December 2, 2004
    Inventors: Rimona Margalit, Dan Peer
  • Publication number: 20040054014
    Abstract: A method of treating a subject having cancer, particularly a multidrug resistance cancer, which comprises administering to the subject at least one chemotherapeutic agent and at least one 3-aryloxy-3-phenylpropylamine and pharmaceutical compositions and kits for implementing the method.
    Type: Application
    Filed: March 10, 2003
    Publication date: March 18, 2004
    Applicant: Ramot At Tel Aviv University Ltd.
    Inventors: Rimona Margalit, Dan Peer
  • Publication number: 20040006043
    Abstract: A pharmaceutical composition which comprises a chemotherapeutically effective amount of one or more chemotherapeutic agent(s), being entrapped in a drug carrier, and a chemosensitizing effective amount of one or more chemosensitizing agent(s) and/or a chemoprotecting effective amount of one or more chemoprotecting agent(s) and methods of using same in cancer therapy.
    Type: Application
    Filed: July 2, 2002
    Publication date: January 8, 2004
    Applicant: RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD.
    Inventors: Rimona Margalit, Dan Peer
  • Patent number: 6630454
    Abstract: A method of chemosensitization which comprises administering at least one chemotherapeutic agent and at least one 3-aryloxy-3-phenylpropylamine to a subject in need thereof.
    Type: Grant
    Filed: September 10, 2001
    Date of Patent: October 7, 2003
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Rimona Margalit, Dan Peer
  • Publication number: 20030087964
    Abstract: A method of chemosensitization which comprises administering at least one chemotherapeutic agent and at least one 3-aryloxy-3-phenylpropylamine to a subject in need thereof.
    Type: Application
    Filed: September 10, 2001
    Publication date: May 8, 2003
    Applicant: Ramot University Authority for Applied Research And Industrial Development Ltd.
    Inventors: Rimona Margalit, Dan Peer